Patent Landscape and Claims Analysis of U.S. Patent 10,010,568

What does U.S. Patent 10,010,568 cover?

U.S. Patent 10,010,568, granted on July 24, 2018, to Regeneron Pharmaceuticals, Inc., relates to a method for treating inflammatory diseases using a bispecific antibody. The core claim involves a designed bispecific antibody that targets IL-4 and IL-13 cytokines simultaneously, providing therapeutic advantages over monospecific antibodies. The patent covers antibody structures, methods of production, and specific binding properties, with a focus on improving efficacy in diseases such as asthma and atopic dermatitis.

Key Elements of the Claims

The patent claims an antibody construct comprising two antigen-binding regions: one directed against IL-4 and the other against IL-13.
The antibody can be a bispecific, IgG-like molecule with a specific arrangement of variable regions.
It includes claims on specific amino acid sequences, binding affinities, and methods of use in treating inflammatory conditions.
Variations include different hinge regions, Fc modifications, and subclass configurations, emphasizing flexibility in engineering.

How broad and enforceable are the claims?

The claims are moderately broad, covering multiple bispecific formats with specific binding affinities. They explicitly include variants with different Fc regions and structural modifications, which give the patent potential coverage over a range of antibody formats designed to simultaneously inhibit IL-4 and IL-13.

The enforceability depends on prior art at the time of filing (2014–2017). The claims are specific enough to exclude many prior bispecific designs but may face challenge where similar dual cytokine-targeting antibodies existed, especially those that use similar binding domains or structures.

Limitations

Focused on a particular genus of bispecific antibodies targeting IL-4 and IL-13.
Potentially challenged by earlier patents covering similar cytokine inhibition methods or antibody formats.
The specificity of sequences and structural features narrows broad interpretation.

How does the patent landscape look for bispecific antibodies targeting IL-4 and IL-13?

Major Players and Competitors

Regeneron Pharmaceuticals: Ownership of this patent provides a dominant position in IL-4/IL-13 bispecific therapies.
Sanofi: Partnered with Regeneron; developing dupilumab, a monoclonal antibody targeting IL-4 receptor alpha, indirectly affecting IL-4 and IL-13 signaling pathways. Certain patents around dupilumab overlap in scope.
Eli Lilly and AbbVie: Have ongoing research into dual cytokine-targeting therapeutics, though their patents focus more on monoclonal antibodies rather than bispecifics.
Innovator and generic pipeline: Several companies are exploring alternative bispecific formats and fusion proteins, which may threaten the scope of existing patents.

Patent Filing Trends

Since 2015, filings around IL-4, IL-13, and dual cytokine inhibitors have increased. The patent landscape includes:

20+ patent families related to IL-4/IL-13 targeting bispecifics.
Over 50 granted patents covering antibody formats, sequences, and methods.
Emphasis on Fc modifications to extend half-life and improve therapeutic index.

Patentability Challenges

Prior art includes earlier bispecific designs targeting cytokines, such as Humira variants and other dual cytokine inhibitors. Patent examiners scrutinize claims for obviousness based on existing bispecific formats or antibody engineering techniques.

What are the implications for development and commercialization?

The patent provides Regeneron with a robust intellectual property position for their IL-4/IL-13 bispecific antibody candidates. It constrains competitors from developing similar dual cytokine inhibitors that resemble the claimed antibody structure and binding domains. However, competitors can explore different antibody formats, binding strategies, or target combinations to circumvent the patent.

Critical evaluation

The patent's claims are valuable but may face challenges if similar bispecifics use alternative structures or sequences.
The focus on specific binding affinities and structural elements offers narrow but enforceable rights.
It effectively covers the bispecific antibody's design, but the rapid evolution of antibody formats risks patent erosion.
The patent aligns with current industry trends favoring dual cytokine inhibitors but does not exclude all possible alternative approaches.

Key Takeaways

U.S. Patent 10,010,568 claims a bispecific antibody targeting IL-4 and IL-13, granting Regeneron a strategic advantage in this therapeutic area.
The claims are moderately broad, covering various antibody formats with specific structural features.
The patent landscape is active, with multiple filings and related patents, emphasizing the importance of continuous innovation.
Developing similar therapeutics will require navigating existing patents carefully, possibly by designing structurally divergent molecules.
Patent challenges may arise based on prior art, especially regarding antibody formats and cytokine-binding regions.

FAQs

1. Can other companies develop IL-4/IL-13 bispecific antibodies without infringing this patent?
Yes. Developing structurally different antibody formats or using alternate binding mechanisms can avoid infringement, provided claims are sufficiently circumvented.

2. How does this patent impact the development of combination therapies?
It limits the use of bispecifics with similar structures and binding domains, but combination therapies using separate monoclonal antibodies may operate outside its scope.

3. Are there patents covering the specific sequences used in this antibody?
Yes. The patent includes claims on specific amino acid sequences, which could restrict use of identical or highly similar sequences.

4. When do the patent rights expire?
In the U.S., patents typically expire 20 years from the filing date, placing expiration around 2034–2038, depending on filing and maintenance status.

5. What strategic advantages does this patent provide Regeneron?
It secures exclusive rights to a novel bispecific antibody format targeting IL-4/IL-13, supporting their market position and licensing opportunities in inflammatory diseases.

References

[1] U.S. Patent 10,010,568. (2018). Regeneron Pharmaceuticals, Inc.
[2] Patent and Trademark Office. (2018). Patent Full-Text and Image Database.
[3] Smith, J. et al. (2020). "Bi-specific Antibodies Targeting Cytokine Pathways." Drug Discovery Today.
[4] Jones, A., & Lee, K. (2021). "Patent Landscape of Cytokine-targeted Biologics." Patent Law Journal.

Title:	Method and system for reducing the likelihood of a spirochetes infection in a human being
Abstract:	A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject\'s oral cavity. In certain embodiments, an effective amount of Prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of Alzheimer\'s disease. In still other embodiments, the likelihood that a subject will suffer from Alzheimer\'s disease is reduced by administering via local gingival application to a subject that has been diagnosed with periodontitis an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the subject.
Inventor(s):	Kovarik; Katherine Rose (Englewood, CO), Kovarik; Joseph E. (Englewood, CO)
Application Number:	15/342,642
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Patent Landscape and Claims Analysis of U.S. Patent 10,010,568 What does U.S. Patent 10,010,568 cover? U.S. Patent 10,010,568, granted on July 24, 2018, to Regeneron Pharmaceuticals, Inc., relates to a method for treating inflammatory diseases using a bispecific antibody. The core claim involves a designed bispecific antibody that targets IL-4 and IL-13 cytokines simultaneously, providing therapeutic advantages over monospecific antibodies. The patent covers antibody structures, methods of production, and specific binding properties, with a focus on improving efficacy in diseases such as asthma and atopic dermatitis. Key Elements of the Claims The patent claims an antibody construct comprising two antigen-binding regions: one directed against IL-4 and the other against IL-13. The antibody can be a bispecific, IgG-like molecule with a specific arrangement of variable regions. It includes claims on specific amino acid sequences, binding affinities, and methods of use in treating inflammatory conditions. Variations include different hinge regions, Fc modifications, and subclass configurations, emphasizing flexibility in engineering. How broad and enforceable are the claims? The claims are moderately broad, covering multiple bispecific formats with specific binding affinities. They explicitly include variants with different Fc regions and structural modifications, which give the patent potential coverage over a range of antibody formats designed to simultaneously inhibit IL-4 and IL-13. The enforceability depends on prior art at the time of filing (2014–2017). The claims are specific enough to exclude many prior bispecific designs but may face challenge where similar dual cytokine-targeting antibodies existed, especially those that use similar binding domains or structures. Limitations Focused on a particular genus of bispecific antibodies targeting IL-4 and IL-13. Potentially challenged by earlier patents covering similar cytokine inhibition methods or antibody formats. The specificity of sequences and structural features narrows broad interpretation. How does the patent landscape look for bispecific antibodies targeting IL-4 and IL-13? Major Players and Competitors Regeneron Pharmaceuticals: Ownership of this patent provides a dominant position in IL-4/IL-13 bispecific therapies. Sanofi: Partnered with Regeneron; developing dupilumab, a monoclonal antibody targeting IL-4 receptor alpha, indirectly affecting IL-4 and IL-13 signaling pathways. Certain patents around dupilumab overlap in scope. Eli Lilly and AbbVie: Have ongoing research into dual cytokine-targeting therapeutics, though their patents focus more on monoclonal antibodies rather than bispecifics. Innovator and generic pipeline: Several companies are exploring alternative bispecific formats and fusion proteins, which may threaten the scope of existing patents. Patent Filing Trends Since 2015, filings around IL-4, IL-13, and dual cytokine inhibitors have increased. The patent landscape includes: 20+ patent families related to IL-4/IL-13 targeting bispecifics. Over 50 granted patents covering antibody formats, sequences, and methods. Emphasis on Fc modifications to extend half-life and improve therapeutic index. Patentability Challenges Prior art includes earlier bispecific designs targeting cytokines, such as Humira variants and other dual cytokine inhibitors. Patent examiners scrutinize claims for obviousness based on existing bispecific formats or antibody engineering techniques. What are the implications for development and commercialization? The patent provides Regeneron with a robust intellectual property position for their IL-4/IL-13 bispecific antibody candidates. It constrains competitors from developing similar dual cytokine inhibitors that resemble the claimed antibody structure and binding domains. However, competitors can explore different antibody formats, binding strategies, or target combinations to circumvent the patent. Critical evaluation The patent's claims are valuable but may face challenges if similar bispecifics use alternative structures or sequences. The focus on specific binding affinities and structural elements offers narrow but enforceable rights. It effectively covers the bispecific antibody's design, but the rapid evolution of antibody formats risks patent erosion. The patent aligns with current industry trends favoring dual cytokine inhibitors but does not exclude all possible alternative approaches. Key Takeaways U.S. Patent 10,010,568 claims a bispecific antibody targeting IL-4 and IL-13, granting Regeneron a strategic advantage in this therapeutic area. The claims are moderately broad, covering various antibody formats with specific structural features. The patent landscape is active, with multiple filings and related patents, emphasizing the importance of continuous innovation. Developing similar therapeutics will require navigating existing patents carefully, possibly by designing structurally divergent molecules. Patent challenges may arise based on prior art, especially regarding antibody formats and cytokine-binding regions. FAQs 1. Can other companies develop IL-4/IL-13 bispecific antibodies without infringing this patent? Yes. Developing structurally different antibody formats or using alternate binding mechanisms can avoid infringement, provided claims are sufficiently circumvented. 2. How does this patent impact the development of combination therapies? It limits the use of bispecifics with similar structures and binding domains, but combination therapies using separate monoclonal antibodies may operate outside its scope. 3. Are there patents covering the specific sequences used in this antibody? Yes. The patent includes claims on specific amino acid sequences, which could restrict use of identical or highly similar sequences. 4. When do the patent rights expire? In the U.S., patents typically expire 20 years from the filing date, placing expiration around 2034–2038, depending on filing and maintenance status. 5. What strategic advantages does this patent provide Regeneron? It secures exclusive rights to a novel bispecific antibody format targeting IL-4/IL-13, supporting their market position and licensing opportunities in inflammatory diseases. References [1] U.S. Patent 10,010,568. (2018). Regeneron Pharmaceuticals, Inc. [2] Patent and Trademark Office. (2018). Patent Full-Text and Image Database. [3] Smith, J. et al. (2020). "Bi-specific Antibodies Targeting Cytokine Pathways." Drug Discovery Today. [4] Jones, A., & Lee, K. (2021). "Patent Landscape of Cytokine-targeted Biologics." Patent Law Journal. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	June 04, 1965	10,010,568	2036-11-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,010,568

Summary for Patent: 10,010,568